Search

Your search keyword '"Reda, Gianluigi"' showing total 560 results
Start Over Author "Reda, Gianluigi"
560 results on '"Reda, Gianluigi"'

1. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Al-Shemari, Salem, Aurran-Schleinitz, Thérèse, Bacchiarri, Francesca, Bellido, Mar, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofia, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, Maria, Donaldson, David, Santos, Gimena Dos, Dreta, Barbara, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón-y-Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José-Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Laribi, Kamel, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, Maria, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, Lopez-Garcia, Alberto, Marquet, Juan, Martin-Rodríguez, Lucia, Maynadié, Marc, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Miras, Fatima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, Maria, Papajík, Tomas, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martin, Smirnova, Svetlana, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Tadmor, Tamar, Tomic, Kristina, Tse, Eric, Vassilakopoulos, Theodoros, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Panagiotidis, Panagiotis, Popov, Viola Maria, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine, Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2023
Full Text
View/download PDF

2. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, Riccardo, Rossi, Francesca Maria, Vit, Filippo, Bittolo, Tamara, Zucchetto, Antonella, Papotti, Robel, Tissino, Erika, Pozzo, Federico, Degan, Massimo, Polesel, Jerry, Bulian, Pietro, Marasca, Roberto, Reda, Gianluigi, Laurenti, Luca, Olivieri, Jacopo, Chiarenza, Annalisa, Laureana, Roberta, Postorino, Massimiliano, Del Principe, Maria Ilaria, Cuneo, Antonio, Gentile, Massimo, Morabito, Fortunato, Fronza, Gilberto, Tafuri, Agostino, Zaja, Francesco, Foà, Robin, Di Raimondo, Francesco, Del Poeta, Giovanni, and Gattei, Valter

Published
2023
Full Text
View/download PDF

3. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Author

Bonfiglio, Silvia, Sutton, Lesley-Ann, Ljungström, Viktor, Capasso, Antonella, Pandzic, Tatjana, Weström, Simone, Foroughi-Asl, Hassan, Skaftason, Aron, Gellerbring, Anna, Lyander, Anna, Gandini, Francesca, Gaidano, Gianluca, Trentin, Livio, Bonello, Lisa, Reda, Gianluigi, Bödör, Csaba, Stavroyianni, Niki, Tam, Constantine S., Marasca, Roberto, Forconi, Francesco, Panayiotidis, Panayiotis, Ringshausen, Ingo, Jaksic, Ozren, Frustaci, Anna Maria, Iyengar, Sunil, Coscia, Marta, Mulligan, Stephen P., Ysebaert, Loïc, Strugov, Vladimir, Pavlovsky, Carolina, Walewska, Renata, Österborg, Anders, Cortese, Diego, Ranghetti, Pamela, Baliakas, Panagiotis, Stamatopoulos, Kostas, Scarfò, Lydia, Rosenquist, Richard, and Ghia, Paolo

Published
2023
Full Text
View/download PDF

4. Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Author

Scarfò, Lydia, Heltai, Silvia, Albi, Elisa, Scarano, Eloise, Schiattone, Luana, Farina, Lucia, Moia, Riccardo, Deodato, Marina, Ferrario, Andrea, Motta, Marina, Reda, Gianluigi, Sancetta, Rosaria, Coscia, Marta, Rivela, Paolo, Laurenti, Luca, Varettoni, Marzia, Perotta, Eleonora, Capasso, Antonella, Ranghetti, Pamela, Colia, Maria, and Ghia, Paolo

Published
2022
Full Text
View/download PDF

5. Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).

Author

Oliva, Esther Natalie, Cuzzola, Maria, Porta, Matteo Della, Candoni, Anna, Salutari, Prassede, Palumbo, Giuseppe A., Reda, Gianluigi, Iannì, Giuseppe, Zampini, Matteo, D'Amico, Saverio, Tripepi, Giovanni, Capelli, Debora, Alati, Caterina, Cannatà, Maria Concetta, Niscola, Pasquale, Serio, Bianca, Barillà, Santina, Musto, Pellegrino, Vigna, Ernesto, and Melillo, Lorella Maria Antonia

Subjects
ACUTE myeloid leukemia, OLDER patients, PROGRESSION-free survival, NUCLEOTIDE sequencing, BONE marrow
Abstract

The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction and consolidation therapy. This ancillary study (QOL-ONE Trans-2) evaluated biological changes in bone marrow using Next-Generation Sequencing (NGS). We analyzed baseline, randomization, and 6-month post-remission samples from 24 patients (median age of 71 and 12 males). High-throughput NGS targeted 350 myeloid malignancy-related genes, considering variants with a variant allele frequency ≥ 4%. At diagnosis, all patients had 5 to 17 (median = 10) mutations, with DNMT3A (42%), NPM1 (33%), and TET2 (33%) being most frequent. FANCA mutations in four patients were linked to a higher relapse risk (HR = 4.96, p = 0.02) for DFS at both 2 and 5 years. Further HLA-specific NGS analyses are ongoing to confirm these results and their therapeutic implications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

7. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, Alessandra, Frustaci, Anna Maria, Mauro, Francesca Romana, Chiarenza, Annalisa, Coscia, Marta, Ciolli, Stefania, Reda, Gianluigi, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Baratè, Claudia, Sportoletti, Paolo, Greco, Antonino, Borella, Chiara, Rossi, Valentina, Deodato, Marina, Biagi, Annalisa, Zamprogna, Giulia, Pelle, Angelo Curto, Lapietra, Gianfranco, Vitale, Candida, Morelli, Francesca, Cassin, Ramona, Fresa, Alberto, Cavalloni, Chiara, Postorino, Massimiliano, Ielo, Claudia, Cairoli, Roberto, Di Raimondo, Francesco, Montillo, Marco, and Del Poeta, Giovanni

Published
2021
Full Text
View/download PDF

8. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2021
Full Text
View/download PDF

9. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs

Author

Vitale, Candida, Salvetti, Chiara, Griggio, Valentina, Porrazzo, Marika, Schiattone, Luana, Zamprogna, Giulia, Visentin, Andrea, Vassallo, Francesco, Cassin, Ramona, Rigolin, Gian Matteo, Murru, Roberta, Laurenti, Luca, Rivela, Paolo, Marchetti, Monia, Pennese, Elsa, Gentile, Massimo, Boccellato, Elia, Perutelli, Francesca, Montalbano, Maria Chiara, De Paoli, Lorenzo, Reda, Gianluigi, Orsucci, Lorella, Trentin, Livio, Cuneo, Antonio, Tedeschi, Alessandra, Scarfò, Lydia, Gaidano, Gianluca, Mauro, Francesca Romana, Foà, Robin, Boccadoro, Mario, and Coscia, Marta

Published
2021
Full Text
View/download PDF

10. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

11. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Published
2020
Full Text
View/download PDF

12. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Author

Martino, Enrica Antonia, primary, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Laurenti, Luca, additional, Visentin, Andrea, additional, Frustaci, Annamaria, additional, Vigna, Ernesto, additional, Pepe, Sara, additional, Catania, Gioacchino, additional, Loseto, Giacomo, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sportoletti, Paolo, additional, Del Principe, Maria Ilaria, additional, Laureana, Roberta, additional, Coscia, Marta, additional, Galimberti, Sara, additional, Ferretti, Eleonora, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Polesel, Jerry, additional, Tedeschi, Alessandra, additional, Rossi, Davide, additional, Trentin, Livio, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

14. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

15. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author

Oliva, Esther Natalie, primary, Riva, Marta, additional, Niscola, Pasquale, additional, Santini, Valeria, additional, Breccia, Massimo, additional, Giai, Valentina, additional, Poloni, Antonella, additional, Patriarca, Andrea, additional, Crisà, Elena, additional, Capodanno, Isabella, additional, Salutari, Prassede, additional, Reda, Gianluigi, additional, Cascavilla, Nicola, additional, Ferrero, Dario, additional, Guarini, Attilio, additional, Tripepi, Giovanni, additional, Iannì, Giuseppe, additional, Russo, Emilio, additional, Castelli, Andrea, additional, Fattizzo, Bruno, additional, Beltrami, Germana, additional, Bocchia, Monica, additional, Molteni, Alfredo, additional, Fenaux, Pierre, additional, Germing, Ulrich, additional, Ricco, Alessandra, additional, Palumbo, Giuseppe A., additional, Impera, Stefana, additional, Di Renzo, Nicola, additional, Rivellini, Flavia, additional, Buccisano, Francesco, additional, Stamatoullas-Bastard, Aspasia, additional, Liberati, Anna Marina, additional, Candoni, Anna, additional, Delfino, Ilaria Maria, additional, Arcadi, Maria Teresa, additional, Cufari, Patrizia, additional, Rizzo, Lorenzo, additional, Bova, Irene, additional, D'Errigo, Maria Grazia, additional, Zini, Gina, additional, and Latagliata, Roberto, additional

Published
2023
Full Text
View/download PDF

16. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Author

Sportoletti, Paolo, primary, Laurenti, Luca, additional, Chiarenza, Annalisa, additional, Gaidano, Gianluca, additional, Albi, Elisa, additional, Mauro, Francesca Romana, additional, Trentin, Livio, additional, Vallisa, Daniele, additional, Pane, Fabrizio, additional, Cuneo, Antonio, additional, Albano, Francesco, additional, Zamprogna, Giulia, additional, Coscia, Marta, additional, Gozzetti, Alessandro, additional, Reda, Gianluigi, additional, Caira, Morena, additional, Finsinger, Paola, additional, Gualberti, Giuliana, additional, Iannella, Emilia, additional, Malgieri, Simona, additional, and Molica, Stefano, additional

Published
2023
Full Text
View/download PDF

17. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

18. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.

Author

Chatzikonstantinou, Thomas, primary, Scarfò, Lydia, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Iacoboni, Gloria, additional, Kotaskova, Jana, additional, Demosthenous, Christos, additional, Alcoceba, Miguel, additional, Al-Shemari, Salem, additional, Aurran-Schleinitz, Thérèse, additional, Bacchiarri, Francesca, additional, Bellido, Mar, additional, Bijou, Fontanet, additional, Calleja, Anne, additional, Medina, Angeles, additional, Khan, Mehreen Ali, additional, Cassin, Ramona, additional, Chatzileontiadou, Sofia, additional, Collado, Rosa, additional, Davis, Zadie, additional, Dimou, Maria, additional, Donaldson, David, additional, Santos, Gimena Dos, additional, Dreta, Barbara, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Fresa, Alberto, additional, Galimberti, Sara, additional, Galitzia, Andrea, additional, García-Serra, Rocío, additional, Gimeno, Eva, additional, González-Gascón-Y-Marín, Isabel, additional, Gozzetti, Alessandro, additional, Guarente, Valerio, additional, Guieze, Romain, additional, Gogia, Ajay, additional, Gupta, Ritu, additional, Harrop, Sean, additional, Hatzimichael, Eleftheria, additional, Herishanu, Yair, additional, Hernández-Rivas, José-Ángel, additional, Inchiappa, Luca, additional, Jaksic, Ozren, additional, Janssen, Susanne, additional, Kalicińska, Elżbieta, additional, Kamel, Laribi, additional, Karakus, Volkan, additional, Kater, Arnon P, additional, Kho, Bonnie, additional, Kislova, Maria, additional, Konstantinou, Εliana, additional, Koren-Michowitz, Maya, additional, Kotsianidis, Ioannis, additional, Kreitman, Robert J, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Levin, Mark-David, additional, Levy, Ilana, additional, Longval, Thomas, additional, Lopez-Garcia, Alberto, additional, Marquet, Juan, additional, Maynadié, Marc, additional, Maslejova, Stanislava, additional, Mayor-Bastida, Carlota, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Miras, Fatima, additional, Moia, Riccardo, additional, Morawska, Marta, additional, Murru, Roberta, additional, Nath, Uttam Kumar, additional, Navarro-Bailón, Almudena, additional, Oliveira, Ana C., additional, Olivieri, Jacopo, additional, Oscier, David, additional, Panovska-Stavridis, Irina, additional, Papaioannou, Maria, additional, Papajík, Tomas, additional, Phumphukhieo, Punyarat, additional, Pierie, Cheyenne, additional, Puiggros, Anna, additional, Rani, Lata, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ronson, Aharon, additional, Ruchlemer, Rosa, additional, de Deus Santos, Marcos Daniel, additional, Schipani, Mattia, additional, Schiwitza, Annett, additional, Shen, Yandong, additional, Simkovic, Martin, additional, Smirnova, Svetlana, additional, Sameh Abdelrahman Soliman, Dina, additional, Spacek, Martin, additional, Tadmor, Tamar, additional, Tomic, Kristina, additional, Tse, Eric, additional, Vassilakopoulos, Theodoros, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Tresckow, Julia von, additional, Vrachiolias, George, additional, Vukovic, Vojin, additional, Walewska, Renata, additional, Wasik-Szczepanek, Ewa, additional, Xu, Zhenshu, additional, Yagci, Munci, additional, Yañez, Lucrecia, additional, Yassin, Mohamed, additional, Zuchnicka, Jana, additional, Angelopoulou, Maria, additional, Antic, Darko, additional, Biderman, Bella, additional, Catherwood, Mark, additional, Claus, Rainer, additional, Coscia, Marta, additional, Cuneo, Antonio, additional, Demirkan, Fatih, additional, Espinet, Blanca, additional, Gaidano, Gianluca, additional, Kalashnikova, Olga, additional, Laurenti, Luca, additional, Nikitin, Eugene, additional, Pangalis, Gerassimos A., additional, Panagiotidis, Panagiotis, additional, Mulligan, Stephen, additional, Popov, Viola Maria, additional, Pospisilova, Sarka, additional, Smolej, Lukas, additional, Sportoletti, Paolo, additional, Stavroyianni, Niki, additional, Tam, Constantine, additional, Trentin, Livio, additional, Chatzidimitriou, Anastasia, additional, Bosch, Francesc, additional, Doubek, Michael, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2023
Full Text
View/download PDF

19. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Author

Gentile, Massimo, Martino, Enrica Antonia, Visentin, Andrea, Coscia, Marta, Reda, Gianluigi, Sportoletti, Paolo, Mauro, Francesca Romana, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Vigna, Ernesto, Mendicino, Francesco, Lucia, Eugenio, Bossio, Sabrina, Recchia, Anna Grazia, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Al-Janazreh, Hamdi, Vitale, Candida, Tripepi, Giovanni, D’Arrigo, Graziella, Angeletti, Ilaria, Bomben, Riccardo, Neri, Antonino, Cutrona, Giovanna, Fronza, Gilberto, Di Raimondo, Francesco, Gaidano, Gianluca, Cuneo, Antonio, Foà, Robin, Ferrarini, Manlio, Trentin, Livio, Gattei, Valter, and Morabito, Fortunato

Published
2020
Full Text
View/download PDF

21. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

Author

Gentile, Massimo, Shanafelt, Tait D., Reda, Gianluigi, Mauro, Francesca Romana, Zirlik, Katja, Ciolli, Stefania, Laurenti, Luca, Del Principe, Maria Ilaria, Rossi, Davide, Di Renzo, Nicola, Molica, Stefano, Angrilli, Francesco, Coscia, Marta, Chiarenza, Annalisa, Giordano, Annamaria, Cutrona, Giovanna, Chaffee, Kari G., Parikh, Sameer A., Uccello, Giuseppina, Innocenti, Idanna, Tripepi, Giovanni, D’Arrigo, Graziella, Vigna, Ernesto, Recchia, Anna Grazia, Herishanu, Yair, Shvidel, Lev, Tadmor, Tamar, Cortelezzi, Agostino, Del Poeta, Giovanni, Gaidano, Gianluca, Di Raimondo, Francesco, Neri, Antonino, Ferrarini, Manlio, Foà, Robin, Polliack, Aaron, and Morabito, Fortunato

Published
2018
Full Text
View/download PDF

22. Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Author

Mauro, Francesca R., primary, Giannarelli, Diana, additional, Galluzzo, Clementina M., additional, Visentin, Andrea, additional, Frustaci, Anna M., additional, Sportoletti, Paolo, additional, Vitale, Candida, additional, Reda, Gianluigi, additional, Gentile, Massimo, additional, Levato, Luciano, additional, Murru, Roberta, additional, Armiento, Daniele, additional, Molinari, Maria C., additional, Proietti, Giulia, additional, Pepe, Sara, additional, De Falco, Filomena, additional, Mattiello, Veronica, additional, Barabino, Luca, additional, Amici, Roberta, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Girmenia, Corrado, additional, Trentin, Livio, additional, and Baroncelli, Silvia, additional

Published
2023
Full Text
View/download PDF

23. Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

Author

Zamprogna, Giulia, primary, Frustaci, Anna Maria, additional, Travi, Giovanna, additional, Borella, Chiara, additional, Reda, Gianluigi, additional, Motta, Marina, additional, Deodato, Marina, additional, Bossi, Elisa, additional, Mattiello, Veronica, additional, Ferrari, Maria Beatrice, additional, Cotilli, Giulia, additional, Gambacorti-Passerini, Carlo, additional, Cairoli, Roberto, additional, Puoti, Massimo, additional, and Tedeschi, Alessandra, additional

Published
2023
Full Text
View/download PDF

24. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author

Oliva, Esther Natalie, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Giai, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Cascavilla, Nicola, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Iannì, Giuseppe, Russo, Emilio, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A, Impera, Stefana, Di Renzo, Nicola, Rivellini, Flavia, Buccisano, Francesco, Stamatoullas-Bastard, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Arcadi, Maria Teresa, Cufari, Patrizia, Rizzo, Lorenzo, Bova, Irene, D'Errigo, Maria Grazia, Zini, Gina, and Latagliata, Roberto

Subjects
Settore MED/15
Published
2023

25. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

26. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, and Kotsianidis, Ioannis

Abstract

[Background]: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work., [Methods]: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022., [Findings]: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001)., [Interpretation]: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Published
2023

27. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.

Author

Sportoletti, Paolo, Laurenti, Luca, Chiarenza, Annalisa, Gaidano, Gianluca, Albi, Elisa, Mauro, Francesca Romana, Trentin, Livio, Vallisa, Daniele, Pane, Fabrizio, Cuneo, Antonio, Albano, Francesco, Zamprogna, Giulia, Coscia, Marta, Gozzetti, Alessandro, Reda, Gianluigi, Caira, Morena, Finsinger, Paola, Gualberti, Giuliana, Iannella, Emilia, and Malgieri, Simona

Subjects
CHRONIC lymphocytic leukemia, PATIENT preferences, CHRONIC leukemia, COVID-19 pandemic, QUALITY of life, PROGRESSION-free survival
Abstract

Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment line, and socio‐demographic characteristics in a cross sectional, observational study conducted at 16 Italian hematology centers. Study visits occurred between February and July 2020; 401 adult patients with CLL (201 Watch and Wait (W&W), 200 treated) participated in a discrete choice experiment (DCE), composed of 8 choices between pairs of treatment profiles with different levels of 5 attributes of currently available CLL treatments (length of response, route and duration of administration, risk of side effects including diarrhea, infections, or organ damage). Health‐related quality of life was assessed with the EQ‐5D‐5L, EORTC QLQ‐C30 and QLQ CLL‐16. Previously treated patients had longer disease duration (7 vs. 5 years), higher prevalence of serious comorbidities (45.5% vs. 36.2%) and high‐risk molecular markers (unmutated IGHV 55.6% vs. 17.1%; TP53 mutation 15.2% vs. 4.0%). Health‐related quality of life scores were similar between groups. In the DCE, W&W patients rated "possible occurrence of infections" highest (relative importance [RI] = 36.2%), followed by "treatment and relevant duration" (RI = 28.0%) and "progression‐free survival (PFS)" (RI = 16.9%). Previously treated patients rated "treatment and relevant duration" highest (RI = 33.3%), followed by "possible occurrence of infections" (RI = 28.8%), "possible occurrence of organ damage" (RI = 19.4%), and "PFS" (RI = 9.8%). Concern over infection was rated highest overall; unexpectedly PFS was not among the most important criteria in either group, suggesting that the first COVID‐19 pandemic wave may have influenced patient preferences and concerns about CLL therapy options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Author

Autore, Francesco, Innocenti, Idanna, Reda, Gianluigi, Visentin, Andrea, Vitale, Candida, Piciocchi, Alfonso, Fresa, Alberto, Leone, Monica M. A., Farina, Lucia, Quaresmini, Giulia, Baratè, Claudia, Giordano, Annamaria, Ferrari, Angela, Angeletti, Ilaria, De Paolis, Maria Rosaria, Malerba, Lara, Chiurazzi, Federico, Loseto, Giacomo, Catania, Gioacchino, and Sportoletti, Paolo

Subjects
CHRONIC lymphocytic leukemia, VENETOCLAX, PROGRESSION-free survival, LYMPHADENITIS, LYMPHATIC metastasis, MULTIVARIATE analysis, CHRONIC leukemia
Abstract

Clinical or biological parameters useful to predict progression during treatment in real‐life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi‐center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow‐up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3‐year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)

Author

Oliva, Esther Natalie, primary, Candoni, Anna, additional, Salutari, Prassede, additional, Palumbo, Giuseppe A., additional, Reda, Gianluigi, additional, Iannì, Giuseppe, additional, Tripepi, Giovanni, additional, Cuzzola, Maria, additional, Capelli, Debora, additional, Mammì, Corrado, additional, Alati, Caterina, additional, Cannatà, Maria Concetta, additional, Niscola, Pasquale, additional, Serio, Bianca, additional, Musto, Pellegrino, additional, Vigna, Ernesto, additional, Volpe, Antonio, additional, Melillo, Lorella Maria Antonia, additional, Arcadi, Maria Teresa, additional, Mannina, Donato, additional, Zannier, Maria Elena, additional, and Latagliata, Roberto, additional

Published
2023
Full Text
View/download PDF

30. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Mauro, Francesca Romana, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Moia, Riccardo, additional, Condoluci, Adalgisa, additional, Vincelli, Iolanda, additional, Chiarenza, Annalisa, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mezzatesta, Sabrina, additional, Laureana, Roberta, additional, Cutrona, Giovanna, additional, Di Raimondo, Francesco, additional, Fronza, Gilberto, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Rossi, Francesca Maria, additional, Olivieri, Jacopo, additional, Zaja, Francesco, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Del Principe, Maria Ilaria, additional, Ilariucci, Fiorella, additional, Del Poeta, Giovanni, additional, Ferrarini, Manlio, additional, Neri, Antonino, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

Author

Visco, Carlo, primary, Maura, Francesco, primary, Tuana, Giacomo, primary, Agnelli, Luca, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Novella, Elisabetta, primary, Giaretta, Ilaria, primary, Reda, Gianluigi, primary, Barcellini, Wilma, primary, Baldini, Luca, primary, Neri, Antonino, primary, Rodeghiero, Francesco, primary, and Cortelezzi, Agostino, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure Legends 1-2 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

Author

Visco, Carlo, primary, Maura, Francesco, primary, Tuana, Giacomo, primary, Agnelli, Luca, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Novella, Elisabetta, primary, Giaretta, Ilaria, primary, Reda, Gianluigi, primary, Barcellini, Wilma, primary, Baldini, Luca, primary, Neri, Antonino, primary, Rodeghiero, Francesco, primary, and Cortelezzi, Agostino, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

Author

Visco, Carlo, primary, Maura, Francesco, primary, Tuana, Giacomo, primary, Agnelli, Luca, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Novella, Elisabetta, primary, Giaretta, Ilaria, primary, Reda, Gianluigi, primary, Barcellini, Wilma, primary, Baldini, Luca, primary, Neri, Antonino, primary, Rodeghiero, Francesco, primary, and Cortelezzi, Agostino, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

Author

Visco, Carlo, primary, Maura, Francesco, primary, Tuana, Giacomo, primary, Agnelli, Luca, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Novella, Elisabetta, primary, Giaretta, Ilaria, primary, Reda, Gianluigi, primary, Barcellini, Wilma, primary, Baldini, Luca, primary, Neri, Antonino, primary, Rodeghiero, Francesco, primary, and Cortelezzi, Agostino, primary

Published
2023
Full Text
View/download PDF

36. Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort

Author

Reda, Gianluigi, primary, Mattiello, Veronica, additional, Frustaci, Anna Maria, additional, Visentin, Andrea, additional, Mauro, Francesca Romana, additional, Innocenti, Idanna, additional, Gentile, Massimo, additional, Giannarelli, Diana, additional, Noto, Alessandro, additional, Cassin, Ramona, additional, Neri, Antonino, additional, Laurenti, Luca, additional, and Tedeschi, Alessandra, additional

Published
2023
Full Text
View/download PDF

38. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

Author

Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Vannata, Barbara, Efremov, Dimitar G., Ciolli, Stefania, Del Poeta, Giovanni, Mauro, Francesca Romana, Cortelezzi, Agostino, Borza, Paola Anticoli, Ghio, Francesco, Mondello, Patrizia, Murru, Roberta, Gozzetti, Alessandro, Cariccio, Maria Rosa Lanza, Piccirillo, Nicola, Boncompagni, Riccardo, Cantonetti, Maria, Principe, Maria Ilaria Del, Reda, Gianluigi, Bongarzoni, Velia, Cervetti, Giulia, Pitini, Vincenzo, Foà, Robin, Sica, Simona, and D’Arena, Giovanni

Published
2015
Full Text
View/download PDF

39. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Author

Visentin, Andrea, Mauro, Francesca Romana, Scarfò, Lydia, Gentile, Massimo, Farina, Lucia, Reda, Gianluigi, Ferrarini, Isacco, Proietti, Giulia, Derenzini, Enrico, Cibien, Francesca, Vitale, Candida, Sanna, Alessandro, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Rigolin, Gian Matteo, Sportoletti, Paolo, Trimarco, Valentina, Cavarretta, Chiara Adele, Angotzi, Francesco, Cellini, Alessandro, Ruocco, Valeria, Zatta, Ivan, Laurenti, Luca, Molica, Stefano, Coscia, Marta, Ghia, Paolo, Foà, Robin, Cuneo, Antonio, and Trentin, Livio

Published
2023

40. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

41. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

42. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

Author

Visentin, Andrea, primary, Mauro, Francesca Romana, additional, Catania, Gioachino, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Sanna, Alessandro, additional, Mattiello, Veronica, additional, Cibien, Francesca, additional, Sportoletti, Paolo, additional, Gentile, Massimo, additional, Rigolin, Gian Matteo, additional, Quaglia, Francesca Maria, additional, Murru, Roberta, additional, Gozzetti, Alessandro, additional, Molica, Stefano, additional, Marchetti, Monia, additional, Pravato, Stefano, additional, Angotzi, Francesco, additional, Cellini, Alessandro, additional, Scarfò, Lydia, additional, Reda, Gianluigi, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Ghia, Paolo, additional, Foà, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2022
Full Text
View/download PDF

43. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Author

Molica, Stefano, primary, Scalzulli, Potito Rosario, additional, Scarfò, Lydia, additional, Guarini, Attilio, additional, Murru, Roberta, additional, Sportoletti, Paolo, additional, Frigeri, Ferdinando, additional, Albano, Francesco, additional, Di Renzo, Nicola, additional, Sanna, Alessandro, additional, Innocenti, Idanna, additional, Massaia, Massimo, additional, Coscia, Marta, additional, Pennese, Elsa, additional, Patti, Caterina, additional, Reda, Gianluigi, additional, Tafuri, Agostino, additional, Regazzoni, Giulia, additional, Di Candia, Michele, additional, and Mauro, Francesca Romana, additional

Published
2022
Full Text
View/download PDF

44. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

45. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Baile Gonzales, Monica, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, Garcia-Marco, Jose A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Gomes da Silva, Maria, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Mayor Bastida, Carlota, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Te Raa, Doreen, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Yanez San Segundo, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

46. Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Author

Visentin, Andrea, primary, Mauro, Francesca, additional, Scarfò, Lydia, additional, Gentile, Massimo, additional, Farina, Lucia, additional, Reda, Gianluigi, additional, Ferrarini, Isacco, additional, Proietti, Giulia, additional, Derenzini, Enrico, additional, Cibien, Francesca, additional, Vitale, Candida, additional, Sanna, Alessandro, additional, Catania, Gioachino, additional, Marchetti, Monia, additional, Murru, Roberta, additional, Rigolin, Gian Matteo, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Molica, Stefano, additional, Coscia, Marta, additional, Ghia, Paolo, additional, Foa, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2022
Full Text
View/download PDF

47. How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Author

Frustaci, Annamaria, primary, Piazza, Francesco, additional, Ferrero, Simone, additional, Reda, Gianluigi, additional, Rizzi, Rita, additional, Orsucci, Lorella, additional, Ferrarini, Isacco, additional, Deodato, Marina, additional, Laurenti, Luca, additional, Puccini, Benedetta, additional, Baratè, Claudia, additional, Varettoni, Marzia, additional, Merli, Michele, additional, Cencini, Emanuele, additional, Greco, Antonino, additional, Gini, Guido, additional, Ferrari, Angela, additional, Borella, Chiara, additional, Lista, Enrico, additional, Gentile, Massimo, additional, Murru, Roberta, additional, Motta, Marina, additional, Rezzonico, Francesca, additional, Tani, Monica, additional, Sportoletti, Paolo, additional, Zamprogna, Giulia, additional, Torri, Valter, additional, Cairoli, Roberto, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

48. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.

Author

Oliva, Esther, Iannì, Giuseppe, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Gaidano, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Sanpaolo, Grazia, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Castelli, Andrea, Fattizzo, Bruno, and Beltrami, Germana

Published
2023
Full Text
View/download PDF

49. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia.

Author

Moia, Riccardo, Dondolin, Riccardo, De Propris, Maria Stefania, Talotta, Donatella, Mouhssine, Samir, Perutelli, Francesca, Reda, Gianluigi, Mattiello, Veronica, Rigolin, Gian Matteo, Motta, Marina, Olivieri, Jacopo, Fanin, Renato, Perbellini, Omar, Ferrarini, Isacco, Mauro, Francesca Romana, Del Giudice, Ilaria, Laurenti, Luca, Tomasso, Annamaria, Gentile, Massimo, and Frustaci, Anna Maria

Subjects
CHRONIC lymphocytic leukemia, NUCLEOTIDE sequencing, FLUORESCENCE in situ hybridization, LOW-income countries, CHRONIC leukemia
Abstract

The I EGR2 i gene, coding for a transcription factor that also mediates the I TP53 i dependent apoptotic pathway, was found to be mutated in 3 patients (8.6%), and further stratifies the outcome of low-risk patients. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results